As of February 23, we're $15,600 in the red for the quarter. Donate here to support this vital work
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

GlaxoSmithKline pulls swine flu vaccines in Canada
Key Excerpts from Article on Website of USA Today


USA Today, November 24, 2009
Posted: November 28th, 2009
http://www.usatoday.com/news/health/2009-11-24-glaxo-flu-vac...

Drug company GlaxoSmithKline has told Canadian doctors to stop using one lot of its H1N1 vaccine until an investigation into a higher-than-expected number of severe allergic reactions is completed. The U.S. vaccine will not be identical to Arepanrix, the GSK H1N1 vaccine used in Canada. Arepanrix contains an adjuvant, a substance designed to boost the immune response, but adjuvants have never been approved for use in U.S. flu vaccines. Almost all of the 172,000 doses in question, distributed the week of Nov. 2 to six Canadian provinces, already have been administered, said Geoffrey Matthews, a spokeswoman for the Public Health Agency of Canada, which, with GSK and Health Canada, is investigating cases of anaphylaxis. Symptoms of anaphylaxis include trouble breathing, chest tightness and swelling of the mouth and throat. Six cases have been reported, Matthews says. In the USA, the Vaccine Adverse Event Reporting System said that as of Nov. 13 it had received 116 reports of serious health events related to the vaccine, including eight deaths similar to the number in previous years after a similar number of seasonal flu vaccine doses had been shipped.

Note: For lots more on the risks of swine flu vaccines, click here.


Latest News


Key News Articles from Years Past